{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:35:48Z","timestamp":1793770548027,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00723-z","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T17:49:13Z","timestamp":1742752153000},"page":"829-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia"],"prefix":"10.1007","volume":"14","author":[{"given":"Itay","family":"Perlstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avia","family":"Merenlender Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Elgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthe S.","family":"Zandvliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farina","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuWei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"van Maanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Plock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"Fauchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-4573","authenticated-orcid":false,"given":"Rajendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"723_CR1","unstructured":"Teva Neuroscience, Inc. Uzedy\u2122 (risperidone) extended-release injectable suspension. Parsippany; 2024."},{"issue":"12","key":"723_CR2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343.","journal-title":"Lancet Psychiatry"},{"key":"723_CR3","unstructured":"Janssen Pharmaceutical Companies. Risperdal Consta\u00ae (risperidone) long-acting injection. Titusville; 2021."},{"key":"723_CR4","unstructured":"Shandong Luye Pharmaceutical Co., Ltd. Rykindo\u00ae (risperidone extended-release injectable suspension for intramuscular [IM] use). Yantai, Shandong; 2023."},{"key":"723_CR5","unstructured":"Indivior Inc. Perseris\u2122 (risperidone) for extended-release injectable suspension. North Chesterfield; 2021."},{"issue":"Suppl 3","key":"723_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"723_CR7","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s12325-023-02455-8","volume":"40","author":"DG Robinson","year":"2023","unstructured":"Robinson DG, Suett M, Wilhelm A, et al. Patient and healthcare professional preferences for characteristics of long-acting injectable antipsychotic agents for the treatment of schizophrenia. Adv Ther. 2023;40(5):2249\u201364.","journal-title":"Adv Ther"},{"key":"723_CR8","doi-asserted-by":"crossref","unstructured":"Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH1C.","DOI":"10.4088\/JCP.IN18031AH1C"},{"key":"723_CR9","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"723_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267808","volume":"17","author":"L Lian","year":"2022","unstructured":"Lian L, Kim DD, Procyshyn RM, C\u00e1zares D, Honer WG, Barr AM. Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review. PLoS ONE. 2022;17(4):e0267808.","journal-title":"PLoS ONE"},{"key":"723_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114277","volume":"306","author":"S Lee","year":"2021","unstructured":"Lee S, Schwartz S. Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: a systematic review and meta-analysis of cohort studies. Psychiatry Res. 2021;306:114277.","journal-title":"Psychiatry Res"},{"key":"723_CR12","unstructured":"Merenlender Wagner A, Perlstein I, Elgart A, et al. Exposure-response analysis to assess the relationships between TV-46000 pharmacokinetic exposure parameters, prevention of impending relapse and adverse events. In: 34th Annual Psych Congress, October 29\u2013November 1, 2021 ed. San Antonio, Texas; 2021."},{"issue":"7","key":"723_CR13","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/j.euroneuro.2021.10.436","volume":"53","author":"A Merenlender Wagner","year":"2021","unstructured":"Merenlender Wagner A, Elgart A, Perlstein I, et al. Phase\u00a01 open-label study assessing the pharmacokinetics and safety of TV-46000, a novel long-acting subcutaneous injectable formulation of risperidone. Eur Neuropsychopharmacol. 2021;53(7):S339\u201340.","journal-title":"Eur Neuropsychopharmacol"},{"key":"723_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40263-024-01102-2","volume":"38","author":"JM Kane","year":"2024","unstructured":"Kane JM, Eshet R, Harary E, et al. A long-term safety and tolerability study of TV-46000 for subcutaneous use in patients with schizophrenia: a phase\u00a03, randomized, double-blinded clinical trial. CNS Drugs. 2024;38:625\u201336.","journal-title":"CNS Drugs"},{"issue":"7","key":"723_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cpdd.1078","volume":"11","author":"I Perlstein","year":"2022","unstructured":"Perlstein I, Merenlender Wagner A, Gomeni R, et al. Population pharmacokinetic modeling and simulation of TV-46000: a long-acting injectable formulation of risperidone. Clin Pharmacol Drug Dev. 2022;11(7):865\u201377.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"723_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","volume":"33","author":"AL Nordstr\u00f6m","year":"1993","unstructured":"Nordstr\u00f6m AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33(4):227\u201335.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"723_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1176\/ajp.156.6.869","volume":"156","author":"S Nyberg","year":"1999","unstructured":"Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156(6):869\u201375.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"723_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","volume":"44","author":"KE Vanover","year":"2019","unstructured":"Vanover KE, Davis RE, Zhou Y, et al. Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology. 2019;44(3):598\u2013605.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"723_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","volume":"31","author":"H Uchida","year":"2011","unstructured":"Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(4):497\u2013502.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"723_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/bcp.13246","volume":"83","author":"V Ivaturi","year":"2017","unstructured":"Ivaturi V, Gopalakrishnan M, Gobburu JVS, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. Br J Clin Pharmacol. 2017;83(7):1476\u201398.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"723_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/A:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138.","journal-title":"Pharm Res"},{"issue":"9","key":"723_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/psp4.12217","volume":"6","author":"J Korell","year":"2017","unstructured":"Korell J, Green B, Remmerie B, Vermeulen A. Determination of plasma concentration reference ranges for risperidone and paliperidone. CPT Pharmacometr Syst Pharmacol. 2017;6(9):589\u201395.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"10","key":"723_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/jcph.724","volume":"56","author":"R Gomeni","year":"2016","unstructured":"Gomeni R, Bressolle-Gomeni F, Fava M. Response surface analysis and nonlinear optimization algorithm for maximization of clinical drug performance: application to extended-release and long-acting injectable paliperidone. J Clin Pharmacol. 2016;56(10):1296\u2013306.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"723_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39\u201359.","journal-title":"CNS Drugs"},{"issue":"7\u20138","key":"723_CR25","first-page":"17","volume":"9","author":"JJ Sheehan","year":"2012","unstructured":"Sheehan JJ, Reilly KR, Fu DJ, Alphs L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7\u20138):17\u201323.","journal-title":"Innov Clin Neurosci"},{"issue":"2","key":"723_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase\u00a03 study. J Clin Psychopharmacol. 2016;36(2):130\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"723_CR27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, Eerdekens M, Lindenmayer J, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125\u201332.","journal-title":"Am J Psychiatry"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00723-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:57:50Z","timestamp":1747663070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00723-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00723-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by funding from Teva Branded Pharmaceutical Products R&D LLC. Itay Perlstein has received consultancy fees from Teva Pharmaceuticals in relation to this study. Avia Merenlender Wagner, Anna Elgart, and Rajendra Singh are employees and\/or shareholders of Teva Pharmaceuticals. Anthe Zandvliet, Farina Hellmann, YuWei Lin, Eline van Maanen, Nele Plock, and Floris Fauchet are employees of Certara, which has received payments from Teva Pharmaceuticals in relation to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on data from previously conducted studies and does not contain any new studies with human participants. All involved study centers of the original clinical trials received approval by local ethics committees, and informed consent was received for all patients. Consent was obtained during the original clinical trials, and no new consent forms were required\/collected for this analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}